COVID vaccine safety. Myocarditis

The CDC in the US acknowledges that “an elevated risk for myocarditis among mRNA COVID-19 vaccine recipients has been observed, particularly among males aged 12–29 years”, though this is downplayed in part because there is also “an association between COVID-19 and myocarditis”. Source.

A recent study involving medical researchers from the University of Oxford states: “In males aged less than 40 years, we estimated an additional 3 (95%CI 1, 5) and 12 (95%CI 1, 13) myocarditis events per million in the 1-28 days following a first dose of BNT162b2 [Pfizer/BioNTech] and mRNA-1273 [Moderna], respectively; an additional 14 (95%CI 8, 17), 12 (95%CI 1, 7) and 101 (95%CI 95, 104) myocarditis events following a second dose of ChAdOx1 [AstraZeneca], BNT162b2 and mRNA-1273, respectively; and an additional 13 (95%CI 7, 15) myocarditis events following a third dose of BNT162b2 vaccine. This compares with 7 (95%CI 2, 11) additional myocarditis events in the 1-28 days following a positive SARS-CoV-2 test.” Source.

Okay then.

Note: A little extra for the inquisitive. If there are similar risks of an adverse effect associated with COVID-19 and COVID-19 vaccination, since the latter relies on the former’s spike protein, does the overall risk-benefit analysis factor in the fact that the unvaccinated person may never actually acquire COVID-19 while the vaccinated person has definitely received the vaccine? And are the additional risks associated with potentially ongoing booster shots factored into this analysis?